## Edgar Filing: BIOMARIN PHARMACEUTICAL INC - Form 8-K

BIOMARIN PHARMACEUTICAL INC Form 8-K July 15, 2002

\_\_\_\_\_

#### SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): July 15, 2002

BioMarin Pharmaceutical Inc. (Exact name of registrant as specified in its charter)

Delaware	000-26727	68-0397820
(State or other jurisdiction of	(Commission	(IRS Employer
incorporation or organization)	File Number)	Identification No.)

371 Bel Marin Keys Boulevard, Suite 210, Novato, California94949(Address of principal executive offices)(Zip Code)

Registrant's telephone number, including area code: (415) 884-6700

Not Applicable

(Former name or former address, if changed since last report)

Item 5. Other Events.

On July 15, 2002, BioMarin Pharmaceutical Inc. (the "Registrant") announced the appointment of a new Chief Financial Officer and three new members of the Registrant's board of directors. The Registrant's press release issued on July 15, 2002 is attached hereto as Exhibit 99.1.

Item 7. Financial Statements, Pro Forma Financial Statements and Exhibits.

(a) Financial Statements of Business Acquired.

Not Applicable.

(b) Pro Forma Financial Information.

Not Applicable.

(c) Exhibits.

# Edgar Filing: BIOMARIN PHARMACEUTICAL INC - Form 8-K

Exhibit 99.1 Press Release of the Registrant dated July 15, 2002.

## SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

BioMarin Pharmaceutical Inc., a Delaware corporation

Date: July 15, 2002

By: /s/ Fredric D. Price

Fredric D. Price Chairman and Chief Executive Officer

### EXHIBIT INDEX

Exhibit No.	Description
Exhibit 99.1	Press Release of the Registrant dated July 15, 2002.